HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3219-3232

  Nguyen, Tri ^a   Dai, Yun ^a   Attkisson, Elisa ^a   Kramer, Lora ^a   Jordan, Nicholas ^a   Nguyen, Nguyen ^a   Kolluri, Nikhil ^a   Muschen, Markus ^c   Grant, Steven ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APICIDIN; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; CD19 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CRK LIKE PROTEIN; DASATINIB; ENTINOSTAT; GAMMA HISTONE H2AX; HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; IMATINIB; KW 2449; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROTEIN BCL 2; PROTEIN KINASE LYN; REACTIVE OXYGEN METABOLITE; SCAVENGER; STAT5 PROTEIN; SUBERIC BISHYDROXAMATE; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; LEUKEMIA CELL; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ADULT; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; HISTONE DEACETYLASE INHIBITORS; HUMANS; INDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED BALB C; MICE, SCID; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956056274     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0234     Document Type: Article

References (41)

1. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112:4808-17.
2. Carpiuc KT, Stephens JM, Botteman MF, Feng W, Hay JW. A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome- positive acute lymphoblastic leukemia. Expert Opin Pharmacother 2007;8:2775-87. (Pubitemid 350193716)
3. Quintas-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond- exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009;6:535-43.
4. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6:834-48. (Pubitemid 47500507)
5. La RP, Deininger MW. Resistance to imatinib: mutations and beyond. Semin Hematol 2010;47:335-43.
6. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia. Blood 2007;110:2242-7.
7. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 2007;8:798-812. (Pubitemid 47462135)
8. Marumoto T, Zhang D, Saya H. Aurora-A-a guardian of poles. Nat Rev Cancer 2005;5:42-50.
9. Shiotsu Y, Kiyoi H, Ishikawa Y, Tanizaki R, Shimizu M, Umehara H, et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009;114:1607-17.
10. Pratz KW, Cortes J, Roboz GJ, Rao N, Arowojolu O, Stine A, et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2008;113:3839-46.
11. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84. (Pubitemid 44348499)
12. Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov 2007;6:1-2.
13. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005;23:3971-93. (Pubitemid 46218700)
14. Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl +human myeloid leukemia cells. Cancer Res 2003;63:2118-26. (Pubitemid 36538615)
15. Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate- sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 2006;12:5869-78. (Pubitemid 44629620)
16. Dai Y, Chen S, Venditti CA, Pei XY, Nguyen TK, Dent P, et al. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood 2008;112:793-804.
17. Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J, et al. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res 2008;14: 6106-15.
18. Okabe S, Tauchi T, Ohyashiki K. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. Ann Hematol 2010;89:1081-7.
19. Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, et al. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl +leukemia cells sensitive and resistant to imatinib mesylate. Clin Cancer Res 2006;12:2239-47.
20. Nguyen TK, Rahmani M, Harada H, Dent P, Grant S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 2007;109:4006-15. (Pubitemid 46641754)
21. Gao N, Kramer L, Rahmani M, Dent P, Grant S. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4- yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-on e (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Mol Pharmacol 2006;70:645-55.
22. Nguyen TK, Rahmani M, Harada H, Dent P, Grant S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 2007;109:4006-15. (Pubitemid 46641754)
23. Sliwinski T, Czechowska A, Szemraj J, Morawiec Z, Skorski T, Blasiak J. STI571 reduces NER activity in BCR/ABL-expressing cells. Mutat Res 2008;654:162-7.
24. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003;63:3637-45.
25. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a celldeath pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 2001;98:10833-8. (Pubitemid 32878706)
26. Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome- positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2010.
27. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib- resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7: 345-56. (Pubitemid 46652483)
28. Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD, et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010;17:427-42.
29. Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006;108:645-52. (Pubitemid 44061366)
30. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, et al. Inhibiition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis of antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005.
31. Seo JH, Wood LJ, Agarwal A, O'Hare T, Elsea CR, Griswold IJ, et al. A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors. Cancer Res 2010;70:7325-35.
32. Shuai K, Halpern J, ten HJ, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996;13:247-54.
33. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102:673-8. (Pubitemid 40282724)
34. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska- Skorska M, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006;108:319-27. (Pubitemid 43990645)
35. Fanta S, Sonnenberg M, Skorta I, Duyster J, Miething C, Aulitzky WE, et al. Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells. Oncogene 2008; 27:4380-4. (Pubitemid 352009999)
36. Subramanian C, Opipari AW Jr, Bian X, Castle VP, Kwok RP. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102: 4842-7. (Pubitemid 40471541)
37. Rosato RR, Almenara JA, Maggio SC, Coe S, Atadja P, Dent P, et al. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol Cancer Ther 2008;7:3285-97.
38. Lee JH, Choy ML, Ngo L, Foster SS, Marks PA. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci U S A 2010;107: 14639-44.
39. Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res 2009;69:4150-8.
40. Moore AS, Blagg J, Linardopoulos S, Pearson AD. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 2010;24: 671-8.
41. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-9. (Pubitemid 43801382)